Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.69 |
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19538014 | 1.00 | RAB9A (0.69) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL29675037 | 0.81 | NPC1 (0.59) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL19520633 | 0.81 | NPC1 (0.59) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL20931218 | 0.78 | NPC1 (0.67) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL19538025 | 0.78 | ALDH1A1 (0.64) | RAB9ANPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL19537834 | 0.78 | RAB9A (0.85) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL29675160 | 0.78 | ALDH1A1 (0.64) | RAB9ANPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL29894011 | 0.78 | RAB9A (0.85) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL20931214 | 0.78 | RXFP1 (0.69) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL29894125 | 0.78 | RXFP1 (0.69) | RAB9ANPC1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153655-B | Novel N-acylurea derivatives and compositions comprising the same for preventing or treating cardiovascular diseases | 高丽大学校产学协力团 | 2022-09-30 | — | — | CN | claimed |
| CN-109153655-B | Novel N-acylurea derivatives and compositions comprising the same for preventing or treating cardiovascular diseases | 高丽大学校产学协力团 | 2022-09-30 | — | — | CN | disclosed |
| US-20220194928-A1 | NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194928-A1 | NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE | TLN1, TNNI3, PTK2 | RAB9A 1229/4885NPC1 1523/4885KMT2A 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.